Cargando…

P2R Inhibitors Prevent Antibody-Mediated Complement Activation in an Animal Model of Neuromyelitis Optica: P2R Inhibitors Prevent Autoantibody Injury

Purinergic 2 receptors (P2Rs) contribute to disease-related immune cell signaling and are upregulated in various pathological settings, including neuroinflammation. P2R inhibitors have been used to treat inflammatory diseases and can protect against complement-mediated cell injury. However, the mech...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalluri, Sudhakar Reddy, Srivastava, Rajneesh, Kenet, Selin, Tanti, Goutam K., Dornmair, Klaus, Bennett, Jeffrey L., Misgeld, Thomas, Hemmer, Bernhard, Wyss, Matthias T., Herwerth, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606199/
https://www.ncbi.nlm.nih.gov/pubmed/35821382
http://dx.doi.org/10.1007/s13311-022-01269-w
_version_ 1784818239586435072
author Kalluri, Sudhakar Reddy
Srivastava, Rajneesh
Kenet, Selin
Tanti, Goutam K.
Dornmair, Klaus
Bennett, Jeffrey L.
Misgeld, Thomas
Hemmer, Bernhard
Wyss, Matthias T.
Herwerth, Marina
author_facet Kalluri, Sudhakar Reddy
Srivastava, Rajneesh
Kenet, Selin
Tanti, Goutam K.
Dornmair, Klaus
Bennett, Jeffrey L.
Misgeld, Thomas
Hemmer, Bernhard
Wyss, Matthias T.
Herwerth, Marina
author_sort Kalluri, Sudhakar Reddy
collection PubMed
description Purinergic 2 receptors (P2Rs) contribute to disease-related immune cell signaling and are upregulated in various pathological settings, including neuroinflammation. P2R inhibitors have been used to treat inflammatory diseases and can protect against complement-mediated cell injury. However, the mechanisms behind these anti-inflammatory properties of P2R inhibitors are not well understood, and their potential in CNS autoimmunity is underexplored. Here, we tested the effects of P2R inhibitors on glial toxicity in a mouse model of neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a destructive CNS autoimmune disorder, in which autoantibodies against astrocytic surface antigen Aquaporin 4 (AQP4) mediate complement-dependent loss of astrocytes. Using two-photon microscopy in vivo, we found that various classes of P2R inhibitors prevented AQP4-IgG/complement-dependent astrocyte death. In vitro, these drugs inhibited the binding of AQP4-IgG or MOG-IgG to their antigen in a dose-dependent manner. Size-exclusion chromatography and circular dichroism spectroscopy revealed a partial unfolding of antibodies in the presence of various P2R inhibitors, suggesting a shared interference with IgG antibodies leading to their conformational change. Our study demonstrates that P2R inhibitors can disrupt complement activation by direct interaction with IgG. This mechanism is likely to influence the role of P2R inhibitors in autoimmune disease models and their therapeutic impact in human disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13311-022-01269-w.
format Online
Article
Text
id pubmed-9606199
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-96061992022-11-29 P2R Inhibitors Prevent Antibody-Mediated Complement Activation in an Animal Model of Neuromyelitis Optica: P2R Inhibitors Prevent Autoantibody Injury Kalluri, Sudhakar Reddy Srivastava, Rajneesh Kenet, Selin Tanti, Goutam K. Dornmair, Klaus Bennett, Jeffrey L. Misgeld, Thomas Hemmer, Bernhard Wyss, Matthias T. Herwerth, Marina Neurotherapeutics Original Article Purinergic 2 receptors (P2Rs) contribute to disease-related immune cell signaling and are upregulated in various pathological settings, including neuroinflammation. P2R inhibitors have been used to treat inflammatory diseases and can protect against complement-mediated cell injury. However, the mechanisms behind these anti-inflammatory properties of P2R inhibitors are not well understood, and their potential in CNS autoimmunity is underexplored. Here, we tested the effects of P2R inhibitors on glial toxicity in a mouse model of neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a destructive CNS autoimmune disorder, in which autoantibodies against astrocytic surface antigen Aquaporin 4 (AQP4) mediate complement-dependent loss of astrocytes. Using two-photon microscopy in vivo, we found that various classes of P2R inhibitors prevented AQP4-IgG/complement-dependent astrocyte death. In vitro, these drugs inhibited the binding of AQP4-IgG or MOG-IgG to their antigen in a dose-dependent manner. Size-exclusion chromatography and circular dichroism spectroscopy revealed a partial unfolding of antibodies in the presence of various P2R inhibitors, suggesting a shared interference with IgG antibodies leading to their conformational change. Our study demonstrates that P2R inhibitors can disrupt complement activation by direct interaction with IgG. This mechanism is likely to influence the role of P2R inhibitors in autoimmune disease models and their therapeutic impact in human disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13311-022-01269-w. Springer International Publishing 2022-07-12 2022-09 /pmc/articles/PMC9606199/ /pubmed/35821382 http://dx.doi.org/10.1007/s13311-022-01269-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Kalluri, Sudhakar Reddy
Srivastava, Rajneesh
Kenet, Selin
Tanti, Goutam K.
Dornmair, Klaus
Bennett, Jeffrey L.
Misgeld, Thomas
Hemmer, Bernhard
Wyss, Matthias T.
Herwerth, Marina
P2R Inhibitors Prevent Antibody-Mediated Complement Activation in an Animal Model of Neuromyelitis Optica: P2R Inhibitors Prevent Autoantibody Injury
title P2R Inhibitors Prevent Antibody-Mediated Complement Activation in an Animal Model of Neuromyelitis Optica: P2R Inhibitors Prevent Autoantibody Injury
title_full P2R Inhibitors Prevent Antibody-Mediated Complement Activation in an Animal Model of Neuromyelitis Optica: P2R Inhibitors Prevent Autoantibody Injury
title_fullStr P2R Inhibitors Prevent Antibody-Mediated Complement Activation in an Animal Model of Neuromyelitis Optica: P2R Inhibitors Prevent Autoantibody Injury
title_full_unstemmed P2R Inhibitors Prevent Antibody-Mediated Complement Activation in an Animal Model of Neuromyelitis Optica: P2R Inhibitors Prevent Autoantibody Injury
title_short P2R Inhibitors Prevent Antibody-Mediated Complement Activation in an Animal Model of Neuromyelitis Optica: P2R Inhibitors Prevent Autoantibody Injury
title_sort p2r inhibitors prevent antibody-mediated complement activation in an animal model of neuromyelitis optica: p2r inhibitors prevent autoantibody injury
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606199/
https://www.ncbi.nlm.nih.gov/pubmed/35821382
http://dx.doi.org/10.1007/s13311-022-01269-w
work_keys_str_mv AT kallurisudhakarreddy p2rinhibitorspreventantibodymediatedcomplementactivationinananimalmodelofneuromyelitisopticap2rinhibitorspreventautoantibodyinjury
AT srivastavarajneesh p2rinhibitorspreventantibodymediatedcomplementactivationinananimalmodelofneuromyelitisopticap2rinhibitorspreventautoantibodyinjury
AT kenetselin p2rinhibitorspreventantibodymediatedcomplementactivationinananimalmodelofneuromyelitisopticap2rinhibitorspreventautoantibodyinjury
AT tantigoutamk p2rinhibitorspreventantibodymediatedcomplementactivationinananimalmodelofneuromyelitisopticap2rinhibitorspreventautoantibodyinjury
AT dornmairklaus p2rinhibitorspreventantibodymediatedcomplementactivationinananimalmodelofneuromyelitisopticap2rinhibitorspreventautoantibodyinjury
AT bennettjeffreyl p2rinhibitorspreventantibodymediatedcomplementactivationinananimalmodelofneuromyelitisopticap2rinhibitorspreventautoantibodyinjury
AT misgeldthomas p2rinhibitorspreventantibodymediatedcomplementactivationinananimalmodelofneuromyelitisopticap2rinhibitorspreventautoantibodyinjury
AT hemmerbernhard p2rinhibitorspreventantibodymediatedcomplementactivationinananimalmodelofneuromyelitisopticap2rinhibitorspreventautoantibodyinjury
AT wyssmatthiast p2rinhibitorspreventantibodymediatedcomplementactivationinananimalmodelofneuromyelitisopticap2rinhibitorspreventautoantibodyinjury
AT herwerthmarina p2rinhibitorspreventantibodymediatedcomplementactivationinananimalmodelofneuromyelitisopticap2rinhibitorspreventautoantibodyinjury